Jack Cush

Dallas

Executive Editor at RheumNow

Featured in: Favicon

rheumnow.com Favicon

healio.com

Articles

Nurse-Led Treat-to-Target Clinics | RheumNow

1 week ago | rheumnow.com | Jack Cush

New studies shared at the 2025 annual EULAR congress in Barcelona reinforce that position, highlighting the benefits that nurse-led care can bring for both patients and healthcare systems. Nurse-led care and self-monitoring can both support treat-to-target (T2T) approaches.2,3 Combining self-monitoring with nurse support during the initiation of urate-lowering therapy in people with gout could help reduce physician visits and costs while maintaining or improving quality of care.
EULAR 2025 – Day 4 Report | RheumNow

1 week ago | rheumnow.com | Jack Cush

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following:EULAR Recommendations for the Management of Familial Mediterranean Fever (FMF)The take-home high points were:FMF should be diagnosed and initially treated by an FMF experienced physician.
Pregnancy outcomes in autoinflammatory disease

1 week ago | rheumnow.com | Jack Cush

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual congress of EULAR – showcased findings from 97 women with an autoinflammatory disease.
EULAR 2025 – Day 3 Report | RheumNow

2 weeks ago | rheumnow.com | Jack Cush

Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis (look for these on RheumNow.com or follow us on twitter). Below are a few others that caught my eye today.
Social Determinants of Health in SLE

2 weeks ago | rheumnow.com | Jack Cush

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, and new research into this for both systemic lupus erythematosus (SLE) and inflammatory arthritis was presented at the 2025 annual EULAR congress in Barcelona.
EULAR 2025 – Day 2 Report | RheumNow

2 weeks ago | rheumnow.com | Jack Cush

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today:Neuroimmune Modulation in RESET-RA StudyOP0190 was a phase 3 trial that assessed Vegas nerve stimulation as a means of improving active rheumatoid arthritis (RA).
EULAR 2025 - Day 1 Report

2 weeks ago | buff.ly | Jack Cush

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1. Rheumatoid Factor is Bad News for EGPAAbstract #POS0020. This report from Sorio at all describes 83 EGPA patients who were retrospectively studied and found that 46% were rheumatoid factor (RF) positive.
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis

2 weeks ago | rheumnow.com | Jack Cush

De la Vega et al. have published in Science Translational Medicine the efficacy of an IL-1Ra gene therapy in adults with knee osteoarthritis (OA). In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There were no serious adverse events related to the gene delivery.
Transcranial Direct Current Stimulation is Effective in Fibromyalgia

2 weeks ago | rheumnow.com | Jack Cush

A randomized, controlled clinical trial has shown the efficacy and safety of an at home, self-applied anodal transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain of fibromyalgia (FM) This double-blind, sham-controlled randomized clinical trial enrolled women aged 18 to 65 years with fibromyalgia. Participants were randomized to receive A-tDCS or sham tDCS between April 2022 and April 2024.
Secukinumab Use in Refractory Giant Cell Arteritis

2 weeks ago | rheumnow.com | Jack Cush

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger phase 3 trial, there comes a 6 patient case series also suggesting the efficacy of IL-17 inhibition in GCA, not responding to TCZ. A case series of six GCA patients from three centres in Italy.